Back to search results

Positive Psychology Intervention for Stem Cell Transplant Survivors

This study is testing a phone-based program called PATH for people who have had a hematopoietic stem cell transplant (HSCT). PATH is a positive psychology program that helps you focus on things like gratitude, personal strengths, and physical activity. Researchers want to see if PATH can help reduce anxiety and depression symptoms, and improve your quality of life, compared to standard care. You might be able to join if you are an adult (18 or older) who has had an allogeneic HSCT and are approaching 100 days post-transplant. You also need to be able to speak English or Spanish and have access to a phone. The main goal is to see how your anxiety symptoms change after 10 weeks. The study is currently recruiting 400 participants, but its overall status is unclear.

Study design
This is a randomized clinical trial, meaning participants will be assigned by chance to either receive the PATH intervention or usual care. The study plans to enroll 400 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Anxiety symptoms will be measured at 10 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06328127

Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors

Recruiting
NAAges 18+InterventionalSupportive care
Brigham and Women's Hospital
~400 participants
Updated 2025-11-13 on ClinicalTrials.gov
What's tested:PATH

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Anxiety Symptoms based on the Hospital Anxiety and Depression Scale-Anxiety Subscale
Measured over 10 weeks

Conditions

Hematopoietic Stem Cell Transplant

Explore related trials

Hematopoietic Cell Transplantation

Where it's being run

3 sites across 3 states
Florida1
Massachusetts1
North Carolina1

Study leadership

  • Hermioni Amonoo, MD, MPP, MPH · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital

Who to contact

Hermioni Amonoo, MD, MPP, MPH
[email protected]
617-525-7472
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients (aged 18 years and older) undergoing allogeneic HSCT and are approaching 100-days post-HSCT
Ability to speak, read, and respond to questions in English or Spanish to complete study procedures
Access to a basic telephone

Exclusion

Patients who underwent allogeneic HSCT for benign hematologic conditions
Patients with severe psychiatric or cognitive conditions, such as dementia, determined by their transplant oncologist to make them unable to provide informed consent or comply with study procedures

What this trial measures

  • Anxiety Symptoms based on the Hospital Anxiety and Depression Scale-Anxiety Subscale10 weeks

    Compare anxiety symptoms between the two groups at 10 weeks using the 7-item Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A). The HADS-A subscale ranges from 0-21, with higher scores indicating worse anxiety symptoms.